 Drug Costs
"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2006 | 2 | 1 | 3 | | 2007 | 1 | 0 | 1 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 3 | 2 | 5 | | 2015 | 2 | 1 | 3 | | 2016 | 5 | 1 | 6 | | 2017 | 0 | 5 | 5 | | 2018 | 1 | 0 | 1 | | 2019 | 2 | 1 | 3 | | 2020 | 3 | 1 | 4 | | 2021 | 2 | 0 | 2 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
Zhang J, Bhaumik D, Meltzer D. Decreasing rates of cost-related medication non-adherence by age advancement among American generational cohorts 2004-2014: a longitudinal study. BMJ Open. 2022 05 06; 12(5):e051480.
-
Ackroyd SA, Huang ES, Kurnit KC, Lee NK. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
-
De Avila JL, Meltzer DO, Zhang JX. Prevalence and Persistence of Cost-Related Medication Nonadherence Among Medicare Beneficiaries at High Risk of Hospitalization. JAMA Netw Open. 2021 03 01; 4(3):e210498.
-
Caram MEV, Oerline MK, Dusetzina S, Herrel LA, Modi PK, Kaufman SR, Skolarus TA, Hollenbeck BK, Shahinian V. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020 12 01; 126(23):5050-5059.
-
Major A, Polite BN. Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will. Cancer J. 2020 Jul/Aug; 26(4):304-310.
-
Zhang JX. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition. PLoS One. 2020; 15(6):e0234463.
-
Serritella AV, Strohbehn GW, Goldstein DA, Lichter AS, Ratain MJ. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clin Pharmacol Ther. 2020 09; 108(3):487-493.
-
Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. J Manag Care Spec Pharm. 2019 Jul; 25(7):770-779.
-
Feinstein JA, Hall M, Antoon JW, Thomson J, Flores JC, Goodman DM, Cohen E, Azuine R, Agrawal R, Houtrow AJ, DeCourcey DD, Kuo DZ, Coller R, Gaur DS, Berry JG. Chronic Medication Use in Children Insured by Medicaid: A Multistate Retrospective Cohort Study. Pediatrics. 2019 04; 143(4).
-
Sherman SK, Lange JJ, Dahdaleh FS, Rajeev R, Gamblin TC, Polite BN, Turaga KK. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncol. 2019 02 01; 5(2):236-242.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|